FindTrial
Sign In

Magnesium sulphate for treatment of tetanus in children

To study the efficacy of intravenous magnesium sulphate Infusion as first line therapy in the control of spasms and muscular rigidity in childhood tetanus - No acronym

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011252
Enrollment
30
Registered
2018-01-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Tetanus

Interventions

Intervention1: Intravenous magnesium sulphate infusion: Intravenous magnesium sulphate was started with a loading dose of 100 mg/kg given over 30 minutes followed by an infusion at the rate of 40mg/kg

Sponsors

No sponsor investigator initiated trial
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All consecutive patients (sample size 30) admitted to the PICU with a clinical diagnosis of tetanus were enrolled after taking informed consent.

Exclusion criteria

Exclusion criteria: patients with renal dysfunction ie S. creatinine >1mg/dL or urine output <1mg/kg/hour were excluded

Design outcomes

Primary

MeasureTime frame
time for control of spasms and muscle rigidity time to initiation of feeds, need for additional sedation or paralysis, need for tracheostomy and ventilation Timepoint: 2years—

Secondary

MeasureTime frame
duration of PICU stay and hospitalization complications of the disease and/or therapy, outcome in terms of discharge or death and cause of death in the event of death Timepoint: 2years—

Countries

India

Contacts

Public ContactPreeti Shanbag

ESI-PGIMSR, Model Hospital

pshanbag@gmail.com9869128012

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026